세계의 동물용 피부과 시장 : 제품 유형별, 질환별, 동물 유형별, 투여 경로별, 유통 채널별, 지역별, 기회 및 예측(2018-2032년)

Global veterinary dermatology market is projected to witness a CAGR of 7.12% during the forecast period 2025-2032, growing from USD 17.09 billion in 2024 to USD 29.63 billion in 2032. The demand for veterinary dermatology is significantly rising as it functions as a specialized branch of veterinary medicine to identify and manage animal conditions that affect skin, along with ears, nails, and hair. The specialty covers numerous health problems, which include allergic reactions and infections as well as autoimmune disorders and certain forms of skin cancer.

The veterinary dermatology market is developing as pet owners understand skin health better, while pet populations increase and medical advancements improve diagnostic and treatment methods. Pet owners who focus on animal health have caused a rapid increase in demand for specialized veterinary dermatological services. The market provides various services, which include allergy testing, parasitic treatments, fungal and bacterial infection management, and chronic skin condition therapies. The medical field has developed new topical formulations and immunotherapy alongside minimally invasive diagnostic tools which improve treatment results. Market growth is driven by the widespread occurrence of skin diseases, including atopic dermatitis, alongside pyoderma and seborrhea. Pet allergies together with autoimmune skin diseases have increased in prevalence which drives the rising need for specialty dermatological treatments. The market leader in North America holds regional dominance because of its advanced pet care standards and technological developments and supportive regulations yet Asia-Pacific shows promising growth because of its emerging veterinary infrastructure and growing pet populations. The veterinary dermatology market includes main industry players who provide extensive pharmaceutical products alongside diagnostic devices and accessory items. Veterinary dermatology market growth will persist in the future due to new pet care developments, technological progress and rising knowledge among pet owners and veterinary professionals.

For instance, in August 2024, Boehringer Ingelheim India announced a new distribution agreement with Vvaan Lifesciences Private Limited for their Pet Parasiticide product line. The partnership functions as an essential part of the India Animal Health Accelerated Growth Plan (AGP) to increase market presence and deliver better value to customers within the animal health industry.

Growing Incidence of Skin Disorders in Animals Increased Market Share

The growing incidence of skin disorders in animals has significantly contributed to the increased market share of the veterinary dermatology market. The increasing prevalence of animal skin disorders is driving greater market expansion in veterinary dermatology. The rise in dermatitis, allergies, mange, bacterial, fungal infections and parasitic infestations among animals stems from environmental shifts and poor hygiene practices together with climate variations and rising allergen contact. When skin conditions go untreated animals experience both discomfort and serious health complications. The need for efficient dermatological treatments and veterinary consultations has increased substantially. The rising vigilance among pet owners for immediate medical attention combines with livestock owners purchasing skin care products to protect their animals' health and production. The rising number of dermatological cases has led to increased sales of medicated shampoos, topical creams, antibiotics, and antifungal treatments. Veterinary dermatology maintains strong market growth and has expanded its market share throughout the world.

For instance, in November 2024, Merck & Co., Inc. (US) received a European Commission grant for marketing authorization for BRAVECTO TriUNO, a new formulation of fluralaner for dogs that targets both internal and external parasites. it has also received grants from the regulatory agencies in Peru, Guatemala, Nicaragua, and Costa Rica.

Advancement in Veterinary Dermatology Product Fuel Market Growth

The global veterinary dermatology market experiences substantial expansion because of ongoing product innovations in veterinary dermatology. Topical therapies along with oral medications and medicated shampoos, now provide better treatment options for animal skin disorders that result in improved success rates and convenience. Healthcare providers use modern therapeutic agents, which consist of long-acting injectable antibiotics together with antifungal agents and targeted immunotherapies, to improve therapeutic results while decreasing disease recurrence risks. The integration of dermoscopy with molecular testing methods enables quick and exact skin disease identification across all animal species which includes domestic animals and farm animals. Modern technology allows veterinary dermatology care to deliver better results while simultaneously building greater confidence among veterinarians and pet owners about immediate treatment approaches. The growing availability of specialized dermatological products through online platforms and veterinary pharmacies helps expand market reach which further drives growth. The market will experience ongoing expansion across developed and emerging regions because innovation continues.

Additionally, to support the advancement in the veterinary dermatology market, the government also takes initiatives by approving drugs. For instance, in March 2024, the FDA granted approval of Duotic as a medication that combines terbinafine with betamethasone acetate to treat otitis externa (ear infections) caused by Malassezia pachydermatis in dogs. The veterinary otic medication Duotic stands as the initial FDA-approved treatment for yeast-only otic infections because it does not include antibiotics.

Companion Animals Hold the Largest Global Veterinary Dermatology Market Share

The veterinary dermatology market features companion animals as its leading market segment because owners highly value their pets' health. Dogs and Cats function as the most common household animals which makes their human caregivers focus on animal wellness while boosting the need for specialized skin care. Pet owners now encounter more skin issues in their animals because allergies, together with infections and parasitic infestations, lead to increased market demand. The increased understanding of skin care among pet owners has driven them to seek advanced diagnostic and therapeutic solutions. Veterinary clinics that specialize in dermatology and utilize advanced non-invasive diagnostic methods have boosted accessibility for dermal care of companion animals. The emotional bonds between pet owners and their animals lead them to complete healthcare investments including dermatology to provide healthy and comfortable lives for their pets. Companion animals maintain the highest market share in veterinary dermatology because of these combined market factors.

Additionally, to reduce skin allergies and infection, companies are expanding their presence in dermatology practices for better results and curing pet health. For instance, in October 2024, Animal Dermatology Group, Inc. formally announced the completion of its acquisition of four dermatology specialty practices including Long Green Animal Dermatology from Baldwin, MD along with Nashville Veterinary Dermatology from Nashville, TN and Animal Dermatology & Allergy from Estero, and FL plus Dermatology & Allergy Clinic for Animals from Santa Barbara, CA. The acquisitions demonstrate ADG's dedication to provide modern veterinary dermatology services to pet owners across the country.

North America Dominates the Global Veterinary Dermatology Market Size

North America dominates the veterinary dermatology market because of multiple essential elements. The region has several factors that make it the leading veterinary dermatology market. Pet ownership exists at an elevated level throughout this region since animal caretakers show growing attention to their pets' health needs. Pet owners now recognize the increasing number of skin issues affecting animals, which drives their search for specialized dermatological solutions. Market growth receives substantial support from advanced veterinary healthcare infrastructure and technological innovations. The establishment of major pharmaceutical companies and research institutions enables quicker development of new dermatological products and therapeutic solutions. Market demand increases because pet owners pursue holistic healthcare, while animal skin allergies and infections and other dermatological conditions become more common. Regulatory agencies, together with a growing number of veterinary professionals, work to increase the availability of services. The combination of these elements establishes North America as a leading force in veterinary dermatology which pushes forward both innovation and market expansion across the region.

Additionally, the growing pet population in the United States also helps to dominate this region by increasing demand for veterinary dermatology products for their pets to reduce human infection. For instance, in March 2025, according to the American Pet Products Association (APPA) survey report, 94 million U.S. households now own at least one pet, up from 82 million in 2023.

Impact of U.S. Tariffs on Global Veterinary Dermatology Market

The U.S. applies tariffs to imported veterinary pharmaceuticals and medical supplies, which specifically affect products utilized in dermatological treatments in the veterinary dermatology market. The initial impact of tariffs causes imported products to become more expensive, which results in increased expenses for veterinary establishments and animal owners. This situation might limit access to specialized treatments while blocking new therapeutic developments. Domestic production might increase because of tariffs, which would generate job opportunities and encourage innovation within the U.S. The total market effect depends on tariff size, together with domestic product availability and how veterinary practices and pet owners respond to price adjustments. The effects on patient care and the market.

Key Players Landscape and Outlook

Continuous innovation characterized the landscape of the veterinary dermatology market. Key players have established their strong presence in the veterinary dermatology market through strategic partnerships, collaboration, and acquisition and merger to lead the market. The future looks optimistic because growing pet numbers and animal health government support create steady market expansion.

In September 2024, the U.S. FDA approved Zenrelia (ilunocitinib), which Elanco Animal Health developed as a daily oral Janus kinase (JAK) inhibitor. The medication treats the itching caused by allergic dermatitis, together with atopic dermatitis symptoms in canines that are 12 months of age or older. Zenrelia delivers a focused solution to handle long-term skin conditions that affect dogs.

In June 2023, Zoetis Inc. stated that the U.S. Food and Drug Administration (FDA) approved Apoquel Chewable for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Veterinary Dermatology Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Product Type
    • 5.2.1.1. Antibacterial
    • 5.2.1.2. Antifungal
    • 5.2.1.3. Antiparasitic
    • 5.2.1.4. Others
  • 5.2.2. By Condition
    • 5.2.2.1. Parasitic Infection
    • 5.2.2.2. Infectious Diseases
    • 5.2.2.3. Others
  • 5.2.3. By Animal Type
    • 5.2.3.1. Companion Animals
      • 5.2.3.1.1. Dogs
      • 5.2.3.1.2. Cats
      • 5.2.3.1.3. Horses
      • 5.2.3.1.4. Others
    • 5.2.3.2. Livestock Animals
      • 5.2.3.2.1. Cattle
      • 5.2.3.2.2. Others
  • 5.2.4. By Route of Administration
    • 5.2.4.1. Topical
    • 5.2.4.2. Oral
    • 5.2.4.3. Injectable
  • 5.2.5. By Distribution Channel
    • 5.2.5.1. Hospital Pharmacies
    • 5.2.5.2. Retail
    • 5.2.5.3. E-commerce
  • 5.2.6. By Region
    • 5.2.6.1. North America
    • 5.2.6.2. Europe
    • 5.2.6.3. Asia-Pacific
    • 5.2.6.4. South America
    • 5.2.6.5. Middle East and Africa
  • 5.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Product Type
  • 5.3.2. By Condition
  • 5.3.3. By Animal Type
  • 5.3.4. By Route of Administration
  • 5.3.5. By Distribution Channel
  • 5.3.6. By Region

6. North America Veterinary Dermatology Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Product Type
    • 6.2.1.1. Antibacterial
    • 6.2.1.2. Antifungal
    • 6.2.1.3. Antiparasitic
    • 6.2.1.4. Others
  • 6.2.2. By Condition
    • 6.2.2.1. Parasitic Infection
    • 6.2.2.2. Infectious Diseases
    • 6.2.2.3. Others
  • 6.2.3. By Animal Type
    • 6.2.3.1. Companion Animals
      • 6.2.3.1.1. Dogs
      • 6.2.3.1.2. Cats
      • 6.2.3.1.3. Horses
      • 6.2.3.1.4. Others
    • 6.2.3.2. Livestock Animals
      • 6.2.3.2.1. Cattle
      • 6.2.3.2.2. Others
  • 6.2.4. By Route of Administration
    • 6.2.4.1. Topical
    • 6.2.4.2. Oral
    • 6.2.4.3. Injectable
  • 6.2.5. By Distribution Channel
    • 6.2.5.1. Hospital Pharmacies
    • 6.2.5.2. Retail
    • 6.2.5.3. E-commerce
  • 6.2.6. By Country Share
    • 6.2.6.1. United States
    • 6.2.6.2. Canada
    • 6.2.6.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Veterinary Dermatology Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Product Type
        • 6.3.1.2.1.1. Antibacterial
        • 6.3.1.2.1.2. Antifungal
        • 6.3.1.2.1.3. Antiparasitic
        • 6.3.1.2.1.4. Others
      • 6.3.1.2.2. By Condition
        • 6.3.1.2.2.1. Parasitic Infection
        • 6.3.1.2.2.2. Infectious Diseases
        • 6.3.1.2.2.3. Others
      • 6.3.1.2.3. By Animal Type
        • 6.3.1.2.3.1. Companion Animals
        • 6.3.1.2.3.1.1. Dogs
        • 6.3.1.2.3.1.2. Cats
        • 6.3.1.2.3.1.3. Horses
        • 6.3.1.2.3.1.4. Others
        • 6.3.1.2.3.2. Livestock Animals
        • 6.3.1.2.3.2.1. Cattle
        • 6.3.1.2.3.2.2. Others
      • 6.3.1.2.4. By Route of Administration
        • 6.3.1.2.4.1. Topical
        • 6.3.1.2.4.2. Oral
        • 6.3.1.2.4.3. Injectable
      • 6.3.1.2.5. By Distribution Channel
        • 6.3.1.2.5.1. Hospital Pharmacies
        • 6.3.1.2.5.2. Retail
        • 6.3.1.2.5.3. E-commerce
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Veterinary Dermatology Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Veterinary Dermatology Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Veterinary Dermatology Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Veterinary Dermatology Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Zoetis Inc.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. Elanco Animal Health Incorporated
  • 20.3.3. Merck & Co., Inc.
  • 20.3.4. Virbac S.A.
  • 20.3.5. Boehringer Ingelheim International GmbH
  • 20.3.6. Soparfin SCA
  • 20.3.7. EQT AB
  • 20.3.8. Hester Biosciences Limited
  • 20.3.9. Swedencare AB
  • 20.3.10. Ourofino Saude Animal

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer